Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

MorphoSys AG Investor Presentation 2010

May 19, 2010

291_ip_2010-05-19_521d81c1-bda8-40a6-b4bd-e6b490e01b85.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

Bio€q y uit Europe 2010

Zurich – May 19, 2010

This presentation includes forward forward-looking statements. looking

Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties including changes in business, economic competitive conditions regulatory reforms foreign exchange rate fluctuations and the conditions, reforms, the availability of financing.

These and other risks and uncertainties are detailed in the Company's Annual Report.

C
C
o
m
p
a
n
y		 A
i
d
d
t
t
i
b
d
"
n
n
e
p
e
n
e
n
a
n
o
y
c
o
m
p
a
n
y
f
f
S
S
F
F
k
k
t
t
t
t
k
k
E
E
h
h
T
D
A
X
"
r
a
n
u
r
o
c
x
c
a
n
g
e
e
c
–
M
i
h
/
G
H
Q
i
i
U
K
U
S
t
"
n
c
e
r
m
a
n
s
e
s
n
u
y
,
,
T
h
l
e
c
n
o
o
g
y		 L
L
d
d
i
i
i
H
C
A
L
l
f
t
t
"
e
e
a
a
n
n
g
g
p
r
o
p
r
e
a
r
p
a
o
r
m
y
u
,
S
&
t
d
i
t
d
t
t
t
t
"
r
o
n
g
u
n
s
p
u
e
p
a
e
n
e
s
a
e
T
h
i
t
e
r
a
p
e
c
u		 O
0
i
b
d
b
d
H
C
A
L
7
t
"
e
r
a
n
o
p
r
o
g
r
a
m
s
a
s
e
o
n
v
y
u
S
t
l
l
i
i
t
h
h
i
"
r
o
n
g
a
a
n
c
e
s
w
p
a
r
m
a
c
o
m
p
a
n
e
s
G
i
i
i
b
d
f
l
i
t
t
t
"
r
o
w
n
g
p
r
o
p
r
e
a
r
y
a
n
o
y
p
o
r
o
o
M
i
l
d
l
i
l
l
t
t
"
e
s
o
n
e
s
a
n
r
o
a
e
s
o
n
a
p
r
o
g
r
a
m
s
y
/
R
h
e
s
e
a
r
c
i
i
D
t
a
g
n
o
s
c
s		 A
b
D
S
f
i
b
l
i
k
t
t
t
t
"
e
r
o
e
c
p
r
o
a
e
o
u
g
r
o
w
n
g
m
a
r
e
,
I
i
i
f
d
i
i
k
t
t
t
t
"
n
c
r
e
a
s
n
g
p
e
n
e
r
a
o
n
o
a
g
n
o
s
c
s
m
a
r
e
F
i
i
l
n
a
n
c
a
s		 S
f
€
9
0
t
i
d
i
t
b
i
l
i
t
i
l
l
i
h
"
u
s
a
n
e
p
r
o
a
y
m
o
n
c
a
s
,
f
2
0
0
3
t
d
t
i
i
g
e
n
e
r
a
e
r
o
m
o
p
e
r
a
o
n
s
s
n
c
e

Recent Developments

/
0
1
1
0
:		 /
C
f
O
F
i
t
P
t
i
t
i
P
h
1
b
2
l
i
i
l
T
i
l
M
R
1
0
3
r
s
a
e
n
n
a
s
e
a
n
c
a
r
a
o
r
P
P
i
i
R
R
h
h
t
t
i
i
d
d
A
A
t
t
h
h
i
i
t
t
i
i
E
E
l
l
l
l
d
d
r
o
g
r
a
m
n
e
u
m
a
o
r
r
s
n
r
o
e
0
1
/
1
0
:		 M
h
S
L
i
H
C
A
L
P
L
A
T
I
N
U
M
A
i
b
d
L
i
b
t
t
o
r
p
o
s
c
e
n
s
e
s
n
o
r
a
r
o
y
u
y
y
S
h
i
i
i
R
h
P
h
i
t
o
n
o
g
n
e
s
e
a
r
c
a
r
n
e
r
s
p
0
2
/
1
0
:		 M
h
S
d
G
l
E
d
A
i
b
d
A
l
l
i
t
o
r
p
o
s
a
n
a
a
p
a
g
o
s
p
a
n
n
o
a
n
c
e
y
x
y
0
2
/
1
0
:		 A
b
D
S
S
i
i
f
i
l
I
A
i
b
d
G
i
t
t
t
t
e
r
o
e
c
g
n
c
a
n
y
m
p
r
o
v
e
s
n
o
y
e
n
e
r
a
o
n
S
P
R
t
r
o
c
e
s
s
u
c
c
e
s
s
a
e
s
/
0
5
1
0		 C
S
C
f-
f-
C
F
i
t
H
A
L
b
d
A
t
i
b
d
h
l
i
i
l
P
t
r
s
u
a
s
e
n
o
y
o
w
s
n
c
a
r
o
o
o
o
n
c
e
p
-

HuCALPLATINUM: Technology p Leadership

Modular gene design & construction

  • HuCAL (Human Combinatorial Antibody Library)
  • Antibodies are fully human are
  • HuCAL PLATINUM launched in December 2008
  • Unique, built-in optimization capabilities
  • Robust intellectual property position

Optimization of antibodies delivers superior drug candidates

Current Product Pipeline

N
a
m
e		 P
t
a
r
n
e
r		 T
t
a
r
g
e		 I
d
i
i
t
n
c
a
o
n		 D
i
s
c
o
v
e
r
y		 P
l
i
i
r
e
c
n
c		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
B
H
Q
8
8
0		 N
i
t
o
a
r
s
v		 D
K
K-
1		 C
a
n
c
e
r
d.
n.		 C
t
e
n
o
c
o
r		 d.
n.		 /
I
l
m
m
n
o
o
g
u
y
C
a
n
c
e
r
d.
n.		 N
t
i
o
v
a
r
s		 d.
n.		 d.
n.
G
t
b
a
n
e
n
e
r
u
m
a		 R
h
o
c
e		 β
A
l
i
d-
m
y
o		 A
D		 6
5
P
t		 d
d.
n.		 C
t
e
n
o
c
o
r		 d.
n.		 I
f
l
t
i
n
a
m
m
a
o
n		 a
r
P
r
o
g
r
a		 n
e
r
e
m
s
B
A
Y
7
9-
4
6
2
0		 B
r S
a
y
e
h
i
c
e
r
n
g		 C
X (
A
I
M
N
)		 C
a
n
c
e
r
2
7
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 V
i
*
a
r
o
u
s
3
1
P
t
d
a
r
n
e
r
e
P
r
o
g
r
a
m
s		 V
i
a
r
o
u
s		 V
i
a
r
o
u
s		 V
i
*
a
r
o
u
s
M
O
R
1
0
3		 - G
M
C
S
F
-		 R
A
M
O
R
2
0
2		 - C
D
3
8		 M
l
i
l
M
l
t
u
p
e
y
e
o
m
a
M
O
R
2
0
5		 - d.
n.		 C
a
n
c
e
r		 P
6
r
o
p
r		 i
t
e
a
r
y
M
O
R
1
0
4		 - d.
n.		 I
f
l
i
t
n
a
m
m
a
o
n		 P
r
o
g
r
a		 m
s
M
O
R
1
0
5		 - d.
n.		 I
f
l
i
t
n
a
m
m
a
o
n
M
O
R
2
0
6		 - d.
n.		 C
a
n
c
e
r
d.
n.		 M
O
R
/
N
O
V		 d.
n.		 d.
n.		 1
P
D
r
e-
e
v.		 P
r
o
g
g
r
a
m

* Includes cancer, inflammatory, autoimmune, infectious, musculoskeletal & central nervous system diseases

n.d. – not disclosed

Partnership yp p g s: Typical Terms per Program

T
T
i
i
l
l
i
i
m
e
n
e		 M
2
0
0
4
I
i
t
i
l
d
l,
i
l
d
i
i
t
t
k
"
a
y
:
n
a
e
a
n
c
u
n
g
e
q
u
y
s
a
e
N
N
b
b
2
2
0
0
0
0
7
7
M
j
j
i
i
"
o
v
e
m
e
r
:
a
o
r
e
x
p
a
n
s
o
n
N
b
2
0
1
E
d
b
j
2
i
i
7
t
t
t
t
"
o
e
m
e
r
n
s
e
c
o
e
a
r
e
e
n
s
o
n
o
p
o
n
v
:
u
-y
x
,
i
N
t
o
a
r
s
p
a
s
v
y
…		 €
€
C
C
A
A
2
2
0
0
t
t
h
h
l
l
l
l
i
i
i
i
l
l
d
d
i
i
H
A
A
L
L
"
p
p
r
o
x
m
p
a
e
c
n
o
o
g
y
c
e
n
s
e
n
c
u
n
g
u
f
i
t
l
i
t
i
n
e
r
n
a
z
a
o
n
e
e
s
A
€
2
0
i
h
f
d
i
"
p
p
r
o
m
p
a
n
r
e
s
e
a
r
c
n
n
g
x
u
O
€
2
0
(
)
5
i
l
t
b
b
i
l
i
t
d
j
t
d
"
v
e
r
m
m
e
s
o
n
e
s
p
r
o
a
y
a
u
s
e
R
l
t
i
l
l
l
t
i
d
"
o
y
a
e
s
o
n
a
r
e
s
u
n
g
r
u
g
s
i
N
t
t
o
a
r
s
g
e
s
v
…		 P
f
d
H
C
A
L
f
i
1
0
0
d
i
t
"
r
e
e
r
r
e
a
c
c
e
s
s
o
o
r
s
e
n
o
e
r
s
c
o
e
r
u
u
v
v
y
p
r
o
g
r
a
m
s
C
d
l
t
o
e
v
e
o
p
m
e
n
-
i
t
o
p
o
n		 S
S
h
h
d
d
&
&
f
f
i
i
(
2
0
%
0
0
%
%
)
)
l
l
d
d
d
d
l
l
d
d
t
t
t
t
5
5
t
t
"
a
r
e
c
o
s
s
p
r
o
s
o
n
s
e
e
c
e
c
o
e
e
o
p
e
v
–

p
r
o
g
r
a
m
s
E
l
d
d
c
e
x
u		 M
i
f
i
d
i
t
t
t
t
"
o
s
n
e
c
o
u
s
s
e
a
s
e
a
r
g
e
s
P
t
a
r
n
e
r		 D
i
i
h
i
S
k
"
a
c
a
n
y
o
i
i
i
i
T
T
l
l
m
e
n
e		 M
h
2
0
0
6
I
i
i
l
l
l
i
t
"
a
r
c
n
a
a
a
n
c
e
:
O
b
2
0
0
9
E
i
f
i
f
i
d
i
t
t
t
"
c
o
e
r
e
c
o
n
o
n
e
c
o
s
s
e
a
s
e
:
x
u
u
d
l
e
a
F
o
c
u
s		 D
i
d
d
d
l
l
f
h
i
t
t
t
t
"
s
c
o
e
r
a
n
e
e
e
e
o
o
p
p
m
m
e
e
n
n
o
e
r
a
p
e
c
v
y
v
v
u
i
b
d
i
i
i
i
d
t
t
t
t
t
t
a
n
o
e
s
a
g
a
n
s
c
e
r
a
n
a
r
g
e
s
a
s
s
o
c
a
e
i
h
h
i
l-
i
d
i
f
i
t
t
t
o
s
p
a
a
c
q
r
e
n
e
c
o
n
s
w
u
i
i
i
D
h
a
c
S
k
a
n
o
y
P
a
s
y
…		 f
f
T
t-
i
i
l
i
"
a
r
g
e
s
p
e
c
c
c
e
n
s
e
e
e
s
&
f
f
R
D
d
i
d
d
i
"
u
n
n
g
o
r
r
u
g
s
c
o
v
e
r
y
R
&
D
f
d
i
f
d
l
f
i
f
i
t
t
"
n
n
g
o
r
e
e
o
p
m
e
n
o
n
e
c
o
s
u
v
u
d
i
l
d
h
l
i
t
t
s
e
a
s
e
r
e
a
e
e
c
n
o
o
g
e
s
&
M
i
l
t
l
t
i
l
t
i
d
"
e
s
o
n
e
s
r
o
y
y
a
e
s
o
n
r
e
s
u
n
g
g
r
u
g
g
s
Mo
ho
Sy
A
G
Co
rp
s
mp
an
–		 Up
da
te
Ma
2
0
1
0
y
y
–		 ©
Mo
Mo
ho
ho
Sy
Sy
A
G
Pa
1
0
rp
rp
s
s
g
e
N
a
m
e		 P
t
a
r
n
e
r		 /
T
I
d
i
i
t
t
a
r
g
e
n
c
a
o
n		 P
h
1
a
s
e		 P
h
2
a
s
e		 P
h
3
a
s
e		 M
k
t
a
r
e
B
H
Q
8
8
0		 N
i
t
o
a
r
s
v		 1 M
D
K
K-
l
i
l
M
l
t
p
e
e
o
m
a
u
y		 0
0
2
2
/
/
2
2
0
0
0
0
9
9
S
S
t
t
:
d
i
h
Z
t
t
s
u
y
w		 t
t
h
h
1
1
/
/
a
r
p
a
s
e
i
t
o
m
e
a
n
m
u		 2
2
b
b
i
i
t
t
i
i
c
o
m
n
a
o
n
l
i
l
l
t
p
e
m
e
o
m
a
y
d.
n.		 C
t
e
n
o
c
o
r		 d.
n.
O
l
/
I
P
F
n
c
o
o
g
y		 /
S
1
0
2
0
0
9
t
t
h
2
i
l
:
a
r
p
a
s
e
n
o
n
c
o
o
g
y
1
1
0
0
/
/
2
2
0
0
0
0
8
8
S
S
2
t
t
t
t
h
h
i
i
I
P
F
:
a
r
p
a
s
e
n
d.
n.		 N
t
i
o
v
a
r
s		 d.
n.		 0
6
/
2
0
0
9
S
h
1
t
t
:
a
r
p
a
s
e
/
C
0
5
2
0
1
0
P
h
i
d
:
o
a
c
e
v
e
G
t
b
a
n
e
n
e
r
u
m
a		 R
h
o
c
e		 β
A
l
i
d-
m
y
o
's
A
l
h
i
D
i
z
e
m
e
r
s
e
a
s
e		 2
0
0
9
T
h
1
d
i
l
t
t
o
p
a
s
e
s
e
s
c
o
m
p
e
:
w
u
2
0
1
0
S
h
2
h
d
l
d
t
t
:
a
r
p
a
s
e
s
c
e
u
e		 d
e
d
d.
n
n.		 C
t
e
n
o
c
o
r		 d.
n.
f
I
l
t
i
n
a
m
m
a
o
n		 /
S
S
f
0
6
2
0
0
9
t
t
t
t
h
1
1
i
i
l
t
i
:
a
a
r
r
p
a
s
e
n
n
a
m
m
a		 o
n
B
A
Y
9-
4
6
2
0
7		 B
r S
a
y
e
h
i
c
e
r
n
g		 C
(
)
C
A
I
X
M
N
A
D
-
O
l
n
c
o
o
g
y		 /
S
1
0
2
0
0
9
t
:
0
4
/
2
0
1
0
P
r
:		 t
h
1
a
r
p
a
s
e
l
i
i
l
d
t
e-
c
n
c
a
a		 C
i
t
h
A
D
w
t
A
A
C
R
a
a
  • Potential for first P-o-C data from partnered HuCAL program
  • 4 - 6 INDs with various partners
  • Roche plans to move into Ph 2 in 2010 with Gantenerumab (AD); potentially others

Partnered Business: Projected HuCAL Drugs on the Market

Source: MorphoSys internal statistics & Tufts Centre for the Study of Drug Development

MOR103Proprietary Inflammation Program

M
O
R
1
0
3
i
f
l
l
h
H
C
A
L
i
b
d
i
t
t
t
"
s
a
u
y
u
m
a
n
u
a
n
o
y
a
r
g
e
n
g
G
M
C
S
F
-
P
i
i
d
i
i
h
i
d
h
i
i
t
t
t
t
ƒ
r
m
a
r
y
n
c
a
o
n
:
r
e
u
m
a
o
a
r
r
s
P
i
i
l
i
i
l
d
f
d
i
d
i
i
t
t
r
o
m
s
n
g
p
r
e
-c
n
c
a
a
a
o
r
s
e
c
o
n
n
c
a
o
n
ƒ
T
t
a
r
g
e		 ®
C
l
i
i
l
i
l
i
d
d
i
i
P
P
E
E
R
R
C
C
6
6
l
l
t
"
n
c
a
m
a
e
r
a
s
p
r
o
u
c
e
u
u
s
s
n
n
g
g
c
e
(
C
/
S
)
l
i
l
l
D
M
n
e
r
u
c
e
f
P
h
1
l
l
l
d
6
3
h
l
h
t
t
"
a
s
e
s
u
c
c
e
s
s
u
y
c
o
m
p
e
e
:
e
a
y
l
l
t
t
d
d
b
b
l
l
b
b
l
l
i
i
d
d
l
l
b
b
t
t
l
l
l
l
d
d
i
l
v
v
o
o
u
u
n
n
e
e
e
e
r
r
s
s
o
o
u
u
e
e
n
n
p
p
a
a
c
c
e
e
o
o
-c
c
o
o
n
n
r
r
o
o
e
e
s
n
g
e
-
,
,
,		 i
G
e
n
u		 n
e
d
i
d
a
s
c
e
n
n
g
o
s
e		 b
l
k
b
o
c
u		 t
s
e
r
\$
M
k
1
0
b
t
"
>
a
r
e
n		 t
p
o
e
n		 i
l
t
a
F
h
2
5
%
f
R
A
i
d
l
d
t
t
t
t
t
t
"
e
w
e
r
a
n
o
p
a
e
n
s
a
e
q
u
a
e
y
r
e
a
e
M
k
t
a
r
e		 5
0
%
f
T
N
F
d
d
i
i
h
i
t
t
"
o
-r
e
s
p
o
n
e
r
s
s
o
p
r
e
s
p
o
n
n
g
w
n
2
y
e
a
r
s
B
d
i
i
h
U
S
A
t
t
t
t
t
"
r
o
a
p
a
e
n
p
r
o
e
c
o
n
n
e
I
P		 E
l
i
l
i
d
U
S
i
t
t
t
t
"
c
s
e
c
e
n
s
e
o
g
r
a
n
e
p
a
e
n
c
o
e
r
n
g
x
u
v
v
k
k
f
f
i
i
b
b
d
d
i
i
i
i
G
G
M
M
C
C
S
S
F
F
t
t
t
t
e
s
e
s
o
a
n
o
e
s
a
g
a
n
s
y
u
-
Mo
ho
A
G
Co		 da
i
l
2
0
1
0
te		 ©
Mo
Mo		 ho
ho
A
G		 Pa
1
3
Sy
rp
s
–		 Up
Ap
mp
an
y
r
–		 Sy
Sy
rp
rp
s
s		 g
e

MOR103 – Ph 1b/2a (MSC-1001) in Rheumatoid Arthritis – Clinical Trial Update

  • Trial approved in Germany, Bulgaria, The Netherlands
  • Study in 135 RA patients, randomized, double-blind, placebo-controlled, multiple ascending dose
  • Geographic mix provides access to full spectrum from biologics-pretreated to biologics-naïve RA patients
  • Primary outcome measures: Adverse event rate and safety profile
  • Secondary outcome measures: DAS28, ACR score set measures and EULAR28 response criteria, cytokines, synovitis, bone edema, pharmacokinetics, immunogenicity and patient reported outcomes up to 16 weeks
  • Stable regimen of concomitant RA therapy (including anti-TNFs)
2
0
0
8		 2
0
0
9		 2
0
1
0		 2
0
1
1		 2
0
1
2
P
h
1
P
h
1
b
/
2
a
i
D
A
l
t
a
a
n
a
s
s
y
F
F
i
i
l
l
P
h
b
b
/
/
D
D
1
1
2
2
t
t
n
a
a
a
a

MOR202: The Opp y ortunity

T
t
a
r
g
e		 C
3
8
f
f
f
D
d
t
h
i
;
o
u
n
o
n
e
s
u
r
a
c
e
o
m
a
n
y
m
m
u
n
e
l
l
c
e
s
P
i
i
d
i
t
i
M
l
t
i
l
l
r
m
a
r
y
n
c
a
o
n
:
u
p
e
m
y
e
o
m
a
ƒ
%
f
H
i
l
d
i
9
5
l
t
i
l
l
e
a
v
y
o
v
e
r-
e
x
p
r
e
s
s
e
n
o
m
u
p
e
m
y
e
o
m
a
ƒ
d
l
k
i
l
l
l
i
a
n
s
o
m
e
e
u
e
m
a
c
e
n
e
s
A
t
i
b
d
i
d
l
l-
k
i
l
l
i
n
o
y
n
u
c
e
s
c
e
n
g
ƒ
M
k
t
a
r
e		 M
l
i
l
l
t
p
e
m
e
o
m
a
u
y
:
%
f
1
0
h
t
l
i
l
o
e
m
a
o
o
g
c
a
c
a
n
c
e
r
s
ƒ
%
f
1
l
l
ƒ
o
a
c
a
n
c
e
r
s
%
f
2
d
t
h
ƒ
o
c
a
n
c
e
r
e
a
s
N
t
i
t
h
i
t
h
k
t
ƒ
o
c
u
r
a
v
e
e
r
a
p
e
s
o
n
e
m
a
r
e
M
d
i
i
l
2
4
3
0
t
h
l
l
t
i
t
ƒ
e
a
n
s
u
r
v
v
a
m
o
n
s
a
p
a
e
n
s
-
,
t
l
l
l
e
v
e
n
u
a
y
r
e
a
p
s
e		 T
i
t
a
r
g
e
n
g
a
j
m
a
o
r
n
m
e
u
i
d
l
m
e
c
a
n
e
e
O
h
t
e
r
I
d
i
i
t
n
c
a
o
n
s		 L
k
i
b
i
l
d
t
e
u
e
m
a
e
n
g
e
v
a
u
a
e

major unmet medical need

MOR202 –Development Plan

  • Manufacturing of clinical grade material completed according to plan
  • Clinical material is produced using PER.C6® p g cell-line (Crucell/DSM)
  • Prepare for Ph 1/2 in multiple myeloma in 2011
  • File CTA in Q4 2010
  • R ti l f t d d ti li f MOR202 Rationale for extended timeline of
  • Sharpened competitive profile
  • Longer chronic toxicity study to enable long-term clinical development
  • C titi d t Competitive advantage: Tox speci il bl ( ies available (cross-reacti it t tivity to non-h i t) b t human primate), robust development plan
2
0
0
9		 2
0
1
0		 2
0
1
1
M
f
i
t
a
n
u
a
c
u
r
n
g
S
T
i
i
d
t
t
o
x
c
y
u
y
C
T
A
P
i
t
r
e
p
a
r
a
o
n
C
i
i
T
A
F
l
n
g
S
S
f
f
P
h
/
/
1
1
2
2
t
t
t
t
a
r
o
a

Clinical Pipeline

Number of Partnered and Proprietary Programs at Year-end

Clinical Antibody Pipeline is a Key Value Driver

Opp j ortunities in Two Major Markets

  • Serving research market via catalog comprising over 13,000 products pg ,p industry

  • Building on reputation for quality

  • Drive uptake of HuCAL in diagnostic dust y

  • Exploit opportunities to create truly differentiated products

AbD Serotec –Future Prospects

  • Continue executing the strategy
  • Intensify penetration of Dx market 25 y p
  • Keep investing in organization
  • Expand geographically
  • Strengthen direct sales force in Europe 18.2
  • Tighten distributor network
  • Mid- to long-term plan includes build-up of Asian sales team
  • Financials: Above market top-line growth, continuously improve margins
I
i
l
l
i
E
U
R
n
m
o
n		 E
*
2
0
1
0		 A
2
0
0
9
T
l
G
R
t
o
a
r
o
u
p
e
v
e
n
u
e
s		 8
9
9
3
–		 8
1
0
A
b
D
S
t
e
r
o
e
c		 2
1
2
2
–		 1
9
4.
G
O
i
P
f
i
t
t
r
o
p
p
e
r
a
n
g
r
o
u		 5
9
–		 1
1
4
A
b
D
S
O
i
P
f
i
M
i
t
t
t
e
r
o
e
c
p
e
r
a
n
g
r
o
a
r
g
n		 %
8
%
5
–		 %
5
*
Es
t
im
te
d
b
a
nu
m
e
rs

2010

Increase of total proprietary R&D investment to € 26 – 29 million (2009: € 19.3 million)

2011 – 2012

  • Aiming for 10% - 20% annual revenue growth
  • Maintain profitability while strengthening pipeline pipeline

Shareholder Structure and Key Financials

Key Financials

M
&
t
a
n
a
g
e
m
e
n		 Q
1
2
0
1
0		 Q
1
2
0
0
9
%
7
S
i
B
d
u
p
e
r
v
s
o
r
y
o
a
r
%
5
%
2
1
0
%
7
%		 R
e
v
e
n
u
e
s		 2
0
6		 1
9
1
C
t
f
G
d
S
l
d
o
s
o
o
o
s
o		 1.
7		 1.
7
R
&
D
E
x
p
e
n
s
e
s		 9
3		 8
5
S
G
&
A
E
x
p
e
n
s
e
s
,		 4
9		 4
8
i
i
T
T
l
l
O
O
E
E
t
t
o
a
p
e
r
a
n
g
p
e
n
s
e
s
x		 1
1
5
9		 1
1
4
4
9
9
7
%		 O
i
P
f
i
t
t
p
e
r
a
n
g
r
o		 4
7		 4
2
%
4
4
%
7
%		 f
i
N
P
t
t
e
r
o		 3
2		 3
5

Cash, Cash Equivalents and Available-for-sale Financial Assets as of March 31, 2010:

€ 147 3 illi 147.3 million

Goals 2010

Future Value Creation

Thank You.

www.morphosys.com

Dr. Claudia Gutjahr-Löser

Head of Corporate Communications & IR

Phone +49 ( ) 0 89 / 899 27-122 Fax +49 (0)89 / 899 27-5122 Email [email protected]

More from MorphoSys AG

AGM Information 2024
Aug 27
Delisting Announcement 2024
Aug 5
AGM Information 2024
Jul 19
AGM Information 2024
Jul 19
Declaration of Voting Results & Voting Rights Announcements 2024
Jul 18
Delisting Announcement 2024
Jul 12
Legal Proceedings Report 2024
Jul 12
Report Publication Announcement 2024
Jul 5
Major Shareholding Notification 2024
Jul 2
Declaration of Voting Results & Voting Rights Announcements 2024
Jun 21
View all filings →